AJG: 肠易激综合征不会增加死亡风险

2020-05-04 MedSci原创 MedSci原创

死亡问题是肠易激综合征(IBS)患者寻求医疗治疗的常见驱动因素。关于IBS死亡率的数据很少,基于人群的研究规模有限。本项研究旨在通过大人群样本进行IBS的死亡率的评估。

介绍: 死亡问题是肠易激综合征(IBS)患者寻求医疗治疗的常见驱动因素。关于IBS死亡率的数据很少,基于人群的研究规模有限。本项研究旨在通过大人群样本进行IBS的死亡率的评估。

方法: 研究人员在瑞典进行了一项全国性,以人群为基础的配对队列研究。根据全国住院和门诊专业护理全国注册系统,研究人员从2002年至2016年在瑞典对45524名接受结直肠活检的患者进行了IBS诊断。比较了这些患有IBS的个体与年龄和性别相匹配的参考人群(n = 217316)的总人口和同胞(n = 53228)之间的死亡风险。在单独的分析中,研究人员还检查了粘膜外观对IBS死亡率的作用。最后,检查了41427例未接受大肠活检的IBS患者的死亡率。Cox回归估计的死亡危险比(HRs)。

结果: 在随访期间,IBS个体死亡3290例(9.4 / 1000人年),而参考个体死亡13255例(7.9 / 1000人年),HR为1.10(95%置信区间[CI] ] = 1.05-1.14)。调整混杂因素后,IBS与死亡率无关(HR = 0.96; 95%CI = 0.92-1.00)。将IBS患者与其兄弟姐妹进行比较时,风险估计为中性。活检的基础粘膜外观仅对死亡率产生微不足道的影响,未接受大肠活检的IBS患者的死亡风险没有增加(HR = 1.02; 95%CI = 0.99-1.06)。

讨论: IBS似乎并没有增加死亡的风险。

原始出处:

Staller, Kyle. et al. Mortality Risk in Irritable Bowel Syndrome.Results From a Nationwide Prospective Cohort Study. American journal of Gastroenterology. 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=960604, encodeId=5c5b9606047a, content=<a href='/topic/show?id=b0bc81566c8' target=_blank style='color:#2F92EE;'>#肠易激综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81566, encryptionId=b0bc81566c8, topicName=肠易激综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Mon Apr 26 12:41:46 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057309, encodeId=f198205e3093f, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Jul 05 01:48:13 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255974, encodeId=c4b412559e423, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 06 07:48:13 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431828, encodeId=334714318288b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed May 06 07:48:13 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=960604, encodeId=5c5b9606047a, content=<a href='/topic/show?id=b0bc81566c8' target=_blank style='color:#2F92EE;'>#肠易激综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81566, encryptionId=b0bc81566c8, topicName=肠易激综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Mon Apr 26 12:41:46 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057309, encodeId=f198205e3093f, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Jul 05 01:48:13 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255974, encodeId=c4b412559e423, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 06 07:48:13 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431828, encodeId=334714318288b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed May 06 07:48:13 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
    2020-07-05 minzju5052
  3. [GetPortalCommentsPageByObjectIdResponse(id=960604, encodeId=5c5b9606047a, content=<a href='/topic/show?id=b0bc81566c8' target=_blank style='color:#2F92EE;'>#肠易激综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81566, encryptionId=b0bc81566c8, topicName=肠易激综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Mon Apr 26 12:41:46 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057309, encodeId=f198205e3093f, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Jul 05 01:48:13 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255974, encodeId=c4b412559e423, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 06 07:48:13 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431828, encodeId=334714318288b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed May 06 07:48:13 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=960604, encodeId=5c5b9606047a, content=<a href='/topic/show?id=b0bc81566c8' target=_blank style='color:#2F92EE;'>#肠易激综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81566, encryptionId=b0bc81566c8, topicName=肠易激综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Mon Apr 26 12:41:46 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057309, encodeId=f198205e3093f, content=<a href='/topic/show?id=18982222db' target=_blank style='color:#2F92EE;'>#AJG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2222, encryptionId=18982222db, topicName=AJG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Jul 05 01:48:13 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255974, encodeId=c4b412559e423, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 06 07:48:13 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431828, encodeId=334714318288b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed May 06 07:48:13 CST 2020, time=2020-05-06, status=1, ipAttribution=)]

相关资讯

GUT:认知行为疗法治疗难治性肠易激综合征

研究认为,认知行为疗法对难治性肠易激综合征的治疗效果显著优于常规治疗

Lancet Gastroen Hepatol:传统肠易激综合征治疗手段疗效比较研究

研究认为,在众多传统肠易激综合征治疗手段中,薄荷油胶囊在改善症状,三环类抗抑郁药在改善腹痛方面有优势,但上述研究具有较高的偏倚风险

抑郁和焦虑与抑郁症,肠易激综合征和炎症性肠病患者的躯体症状相关

大脑与肠道可通过脑肠轴(BGA)进行不间断的双向交流。精神疾病常见于胃肠疾病患者,反之亦然。

Gastroenterology: 肠易激综合征患者和胆汁酸吸收不良者患者的粪便微生物群之间的差异

肠易激综合症(IBS)是一种异质性疾病,本项研究分析了有和没有IBS的患者的粪便微生物群差异,以期望可以进行疾病鉴别。

GUT:粪便菌群移植对肠易激综合征患者的疗效

有学者已尝试从健康供体向肠易激综合征(IBS)患者进行粪便菌群移植(FMT)进行疾病治疗。本项研究旨在进行更深入的研究。

Dig Liver Dis: 嗜酸乳杆菌混合物治疗肠易激综合症的疗效分析

在没有完全治愈的治疗方法的情况下,肠易激综合症患者会寻求替代策略,例如益生菌。当前名为LAPIBSS的试验旨在证明嗜酸乳杆菌 2菌株混合物改善肠易激综合症症状的功效。